Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Impact of Infusion Timing on Safety and Efficacy of Anti-CD19 and Anti-BCMA CAR T Therapies | Synapse
March 3, 2026
Impact of Infusion Timing on Safety and Efficacy of Anti-CD19 and Anti-BCMA CAR T Therapies
SI
Sidharth Iyer
TV
Timothy Voorhees
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
ND
Nathan Denlinger
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Ver todo
Puntos clave
Infusion timing significantly impacts the efficacy of CAR T therapies, enhancing patient outcomes.
The analysis observed a notable increase in efficacy rates with optimal infusion timing during treatment.
This observational analysis evaluated the timing of anti-CD19 and anti-BCMA CAR T therapies.
Findings highlight the importance of infusion timing in optimizing clinical outcomes.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Iyer et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76073c6e9836116a2d355
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.250